Sacituzumab tirumotecan for neuroendocrine prostate cancer after chemotherapy
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This study tests a new targeted therapy (sacituzumab tirumotecan) for men with a rare and aggressive form of prostate cancer that has progressed after chemotherapy. The drug is designed to seek out and destroy cancer cells with a specific marker, potentially slowing the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of prostate cancer that has neuroendocrine features (sometimes called small cell or neuroendocrine prostate cancer).
- You must have already received at least 4 cycles of platinum-based chemotherapy (like cisplatin or carboplatin).
- Your cancer must have gotten worse despite your last treatment.
- Your cancer must be measurable (found on scans or lab tests) and have spread to other parts of your body.
- You need to be in generally good health (able to care for yourself and be up and about).
- You must be willing to provide a tissue sample (biopsy) from your tumor for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs for men with aggressive or neuroendocrine prostate cancer that has worsened after previous hormone therapy. The goal is to see if the combination can shrink tumors or slow the disease.
This trial tests a new drug called sacituzumab tirumotecan for penile cancer that has spread or cannot be cured with surgery or radiation. It is for people whose cancer got worse after standard chemotherapy. The drug is given as an infusion and may help shrink tumors or slow the cancer's growth.
This trial tests a new drug, sacituzumab tirumotecan, in people with advanced thymic carcinoma that has spread or cannot be removed with surgery. It is for those whose cancer has gotten worse after at least one round of platinum-based chemotherapy.
This trial tests a new drug called sacituzumab tirumotecan (also known as MK-2870) for people with advanced small bowel cancer that has stopped responding to standard platinum-based chemotherapy. The drug is designed to target a protein called TROP2 on cancer cells and deliver a chemo-like payload directly to them, which may help shrink or control the tumor.
This trial tests a new medication that targets a protein on cancer cells, aiming to shrink tumors or slow their growth. It is for people with advanced neuroendocrine cancer that has not responded to earlier treatments.
This study tests a new combination of two drugs—sacituzumab tirumotecan (a targeted therapy) plus an immunotherapy—for people whose head and neck cancer has returned or spread after standard treatment. The goal is to see if this combination can shrink tumors and delay cancer growth.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.